Topic 397 - microfluidic vortex shedding: a low-cost, high efficiency method for genetic modification to support cell engineering for cell-based immunotherapies
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91022C00053
- Awardee
-
Indee. Inc. UEI SMXHTLFW8M47
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,999,646
Award facts
- Opportunity
-
- BAA75N91021R00068 Solicitation number
- Contract value 100% obligated
- $1,999,646.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 3 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Berkeley, CA 94710, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $1,999,646 |
About this award
This $1,999,646 firm fixed price definitive contract was awarded by the National Cancer Institute to Indee Inc., a biotechnology startup that develops a non-viral delivery platform called Hydropore for engineered cell therapies. The contract, which was set aside for total small businesses, is for research and development services focused on a microfluidic vortex shedding method to enable efficient genetic modification of cells for use in cell-based immunotherapies. This contract builds upon Indee Inc.'s prior SBIR Phase I award from the National Cancer Institute and a separate project grant from the National Institute of Allergy and Infectious Diseases for integrating the Hydropore technology into development and manufacturing pipelines for adoptive cellular immunotherapies. Additionally, Indee Inc. has received a project grant from the National Institute of Diabetes and Digestive and Kidney Diseases to engineer and evaluate chimeric antigen receptor regulatory T cells using its Hydropore platform for the treatment of Type 1 diabetes.
Quick answers
Who was awarded contract 75N91022C00053?
75N91022C00053 was awarded to Indee. Inc. by National Cancer Institute (National Institutes of Health) on September 19, 2022.
How much is contract 75N91022C00053 worth?
The government has obligated $1,999,646 on 75N91022C00053.
Was contract 75N91022C00053 competed?
The extent of competition for 75N91022C00053 was full and open competition after exclusion of sources. The government received 3 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award